Virosome: A virus created specifically to deliver a vaccination
Main Article Content
Abstract
Liposomes are particularly interesting as a novel medication delivery technology because of their potential as gene carriers and capacity to reduce drug toxicity. Optimized lipid components have been developed to prevent the uptake of reticuloendothelial system (RES). The liposome surface has been altered with antibodies or ligands that are recognized by particular cell types in order to increase tissues localization. Liposomes and fusiogenic viral envelope protein have been combined to form new virosomes, which introduce molecules directly into cells, hence improving the efficiency of gene delivery. Efforts had been made to use virosomes as adjuvants or antibodies, and also for means of drug delivery and organics, for therapeutic applications because they are biocompatible, nontoxic, non-auto-immunogenetic and, biodegradable. In contrast with conventional methods of vaccine development, a vaccine based on virosomes represents a new era in the field of immunization since it strikes a balance between acceptability and efficacy because of its immune-stimulating mechanism. The ability of virosomes to function as a therapeutic target and vaccine adjuvant, as well as their capacity to transport a different kind of substances, such as proteins, peptides, and nucleic and their ability to target specific drugs. The main topics of this article are the basics of virosomes, their formulation, composition, and advantages, development, current clinical status, interactions with the immune system, recent developments, and virosome-related research, as well as the safety, effectiveness, and tolerability of vaccines based on virosomes and their prospects for the future.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Mohanraj VJ, Barnes TJ, Prestidge CA. Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins. International journal of pharmaceutics. 2010;392(1-2):285-93.
Champion CI, Kickhoefer VA, Liu G, Moniz RJ, Freed AS, Bergmann LL, et al. A vault nanoparticle vaccine induces protective mucosal immunity. PloS one. 2009;4(4):e5409.
Smith JE, Sapsford KE, Tan W, Ligler FS. Optimization of antibody-conjugated magnetic nanoparticles for target preconcentration and immunoassays. Analytical biochemistry. 2011;410(1):124-32.
Jain KK, Jain KK. The handbook of nanomedicine: Springer; 2008.
Sharma R, Yasir M. Virosomes: a novel carrier for drug delivery. Int J Pharm Tech Res. 2010;2(4):2327-39.
Ludwig C, Wagner R. Virus-like particles—universal molecular toolboxes. Current opinion in biotechnology. 2007;18(6):537-45.
Canal F, Sanchis J, Vicent MJ. Polymer–drug conjugates as nano-sized medicines. Current opinion in biotechnology. 2011;22(6):894-900.
Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Advanced drug delivery reviews. 2000;43(2-3):197-205.
Hug P, Sleight RG. Fusogenic virosomes prepared by partitioning of vesicular stomatitis virus G protein into preformed vesicles. Journal of Biological Chemistry. 1994;269(6):4050-6.
Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. International immunology. 2005;17(6):695-704.
Cusi MG. Applications of influenza virosomes as a delivery system. Human vaccines. 2006;2(1):1-7.
Felnerova D, Viret J-F, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Current opinion in biotechnology. 2004;15(6):518-29.
Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 2002;20(17-18):2287-95.
Mischler R, Metcalfe IC. Inflexal® V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20:B17-B23.
Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine. 2005;23(10):1232-41.
Huckriede A, Bungener L, Daemen T, Wilschut J. Influenza virosomes in vaccine development. Methods in enzymology. 373: Elsevier; 2003. p. 74-91.
Durrer P, Galli C, Hoenke S, Corti C, Glück R, Vorherr T, et al. H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. Journal of Biological Chemistry. 1996;271(23):13417-21.
Han X, Bushweller JH, Cafiso DS, Tamm LK. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin. Nature structural biology. 2001;8(8):715-20.
Schoen P, Leserman L, Wilschut J. Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions. FEBS letters. 1996;390(3):315-8.
Günther-Ausborn S, Schoen P, Bartoldus I, Wilschut J, Stegmann T. Role of hemagglutinin surface density in the initial stages of influenza virus fusion: lack of evidence for cooperativity. Journal of virology. 2000;74(6):2714-20.
Hernandez LD, Hoffman LR, Wolfsberg TG, White JM. Virus-cell and cell-cell fusion. Annual review of cell and developmental biology. 1996;12(1):627-61.
Weber T, Paesold G, Galli C, Mischler R, Semenza G, Brunner J. Evidence for H (+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. Journal of Biological Chemistry. 1994;269(28):18353-8.
Kim CU, Chen X, Mendel DB. Neuraminidase inhibitors as anti-influenza virus agents. Antiviral Chemistry and Chemotherapy. 1999;10(4):141-54.
Huckriede A, Bungener L, ter Veer W, Holtrop M, Daemen T, Palache AM, et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine. 2003;21(9-10):925-31.
Mizuguchi H, Nakanishi M, Nakanishi T, Nakagawa T, Nakagawa S, Mayumi T. Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. British journal of cancer. 1996;73(4):472-6.
Nakanishi T, Hayashi A, Kunisawa J, Tsutsumi Y, Tanaka K, Yashiro‐Ohtani Y, et al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. European Journal of Immunology. 2000;30(6):1740-7.
Bron R, Ortiz A, Wilschut J. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). Biochemistry. 1994;33(31):9110-7.
Hayashi A, Nakanishi T, Kunisawa J, Kondoh M, Imazu S, Tsutsumi Y, et al. A novel vaccine delivery system using immunopotentiating fusogenic liposomes. Biochemical and biophysical research communications. 1999;261(3):824-8.
Angel J, Chaperot L, Molens J-P, Mezin P, Amacker M, Zurbriggen R, et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine. 2007;25(19):3913-21.
Ye Y, Gaugler B, Mohty M, Malard F. Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases. Clinical & translational immunology. 2020;9(5):e1139.
Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975-1028.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-52.
Cusi MG, Del Vecchio MT, Terrosi C, Savellini GG, Di Genova G, La Placa M, et al. Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. The Journal of Immunology. 2005;174(11):7210-6.
Dijkstra J, Bron R, Wilschut J, De Haan A, Ryan JL. Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). Journal of immunology (Baltimore, Md: 1950). 1996;157(3):1028-36.
Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. Journal of virology. 1994;68(6):3499-504.
Zurbriggen R, Glück R. Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine. 1999;17(11-12):1301-5.
Glück R, Mischler R, Finkel B, Que JU, Cryz Jr SJ, Scarpa B. Immunogenicity of new virosome influenza vaccine in elderly people. The Lancet. 1994;344(8916):160-3.
Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine. 2000;18(14):1327-33.
Leroux-Roels G, Maes C, Clement F, Van Engelenburg F, van den Dobbelsteen M, Adler M, et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PloS one. 2013;8(2):e55438.
Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharmaceutical research. 2011;28:215-36.
Babar MM, Najam-us-Sahar Sadaf Zaidi A, Kazi G, Rehman A. Virosomes-Hybrid drug delivery systems. LIPOSOME & NANOTECHNOLOGY. 2013:415.
Widjaja L, Ilyushina N, Webster RG, Webby RJ. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology. 2006;350(1):137-45.
Geerligs H, Spijkers I, Rodenberg J. Efficacy and Safety of Cell-Associated Vaccines Against Marek's Disease Virus Grown in QT35 Cells or JBJ-1 Cells. Avian Diseases. 2013;57(2s1):448-53.
Nunes-Correia I, Eulálio A, Nir S, Düzgünes N, Ramalho-Santos J, de Lima MCP. Fluorescent probes for monitoring virus fusion kinetics: comparative evaluation of reliability. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2002;1561(1):65-75.
Stegmann T, Morselt HW, Booy FP, Van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. The EMBO journal. 1987;6(9):2651-9.
Bhattacharya S, Mazumder B. Virosomes: A novel strategy for drug delivery and targeting. BioPharm International. 2011;2011(1).
Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58-83.
Carmona-Ribeiro AM. Biomimetic nanoparticles: preparation, characterization and biomedical applications. International journal of nanomedicine. 2010:249-59.
Tofoli GR, Cereda CMS, Groppo FC, Volpato MC, Franz-Montan M, Ranali J, et al. Efficacy of liposome-encapsulated mepivacaine for infiltrative anesthesia in volunteers. Journal of liposome research. 2011;21(1):88-94.
Deniger DC, Kolokoltsov AA, Moore AC, Albrecht TB, Davey RA. Targeting and penetration of virus receptor bearing cells by nanoparticles coated with envelope proteins of Moloney murine leukemia virus. Nano letters. 2006;6(11):2414-21.
Moser C, Metcalfe IC, Viret J-F. Virosomal adjuvanted antigen delivery systems. Expert review of vaccines. 2003;2(2):189-96.
Wang Y, Li B, Luo Y, Yang T, Zhao X, Ding P. Virosome, a promising delivery vehicle for siRNA delivery and its novel preparation method. Journal of Drug Delivery Science and Technology. 2022;74:103490.
Wang Y, Li B, Luo Y, Yang T, Zhao X, Ding PJJoDDS, et al. Virosome, a promising delivery vehicle for siRNA delivery and its novel preparation method. 2022;74:103490.
Mineev KS, Lyukmanova EN, Krabben L, Serebryakova MV, Shulepko MA, Arseniev AS, et al. Structural investigation of influenza virus hemagglutinin membrane-anchoring peptide. 2013;26(9):547-52.
Bundy BC, Franciszkowicz MJ, Swartz JRJB, bioengineering. Escherichia coli‐based cell‐free synthesis of virus‐like particles. 2008;100(1):28-37.
Stockley PG, Stonehouse NJ, Walton C, Walters DA, Medina G, Macedo JM, et al. Molecular mechanism of RNA-phage morphogenesis. Portland Press Ltd.; 1993.
Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang LJTFj. Development of a microRNA delivery system based on bacteriophage MS2 virus‐like particles. 2012;279(7):1198-208.
Wei B, Wei Y, Zhang K, Wang J, Xu R, Zhan S, et al. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide. 2009;63(4):313-8.
Blissard GW, Wenz JRJJov. Baculovirus gp64 envelope glycoprotein is sufficient to mediate pH-dependent membrane fusion. 1992;66(11):6829-35.
Bagai S, Sarkar DPJBeBA-B. Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells. 1993;1152(1):15-25.
Mizuguchi H, Nakanishi T, Kondoh M, Nakagawa T, Nakanishi M, Matsuyama T, et al. Fusion of Sendai virus with liposome depends on only F protein, but not HN protein. 1999;59(2):191-201.
Verma SK, Mani P, Sharma NR, Krishnan A, Kumar VV, Reddy BS, et al. Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery. 2005;280(42):35399-409.
Stevenson P, Doherty PJToIOBS. Cell-mediated immune response to influenza virus. 1998:278-86.
Parker CE, Gould KG, editors. Influenza A virus—a model for viral antigen presentation to cytotoxic T lymphocytes. Seminars in Virology; 1996: Elsevier.
Baumgarth NJIr. A two-phase model of B-cell activation. 2000;176:171-80.
Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen TJV. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. 2000;18(14):1327-33.
Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen TJV. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. 2005;23(10):1232-41.
Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. 2004;350(9):896-903.
Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. 2009;4(9):e6999.
de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache BJV. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. 2007;26(1):119-27.
Ali H, Akbar M, Iqbal B, Ali F, Sharma NK, Kumar N, et al. Virosome: An engineered virus for vaccine delivery. 2023.
Schaller M, Bein M, Korting HC, Baur S, Hamm G, Monod M, et al. The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium. Infection and immunity. 2003;71(6):3227-34.
Wiedermann U, Wiltschke C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast cancer research and treatment. 2010;119:673-83.
Ali H, Akbar M, Iqbal B, Ali F, Sharma NK, Kumar N, et al. Virosome: An engineered virus for vaccine delivery. Saudi Pharmaceutical Journal. 2023.
Huckriede A, De Jonge J, Holtrop M, Wilschut J. Cellular delivery of siRNA mediated by fusion-active virosomes. Journal of liposome research. 2007;17(1):39-47.
Hayat SMG, Nanovaccine MD. A novel approach in immunization., 2019, 234. DOI: https://doi org/101002/jcp.28120:12530-6.
Lamb YNJD. BNT162b2 mRNA COVID-19 vaccine: first approval. 2021;81:495-501.
Sa S, Lee CW, Shim SR, Yoo H, Choi J, Kim JH, et al. The safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 vaccines: safety monitoring for adverse events using real-world data. Vaccines. 2022;10(2):320.
Mikule E, Reissaar T, Villers J, Takoupo Penka AS, Temerev A, Rozanova L. The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations? Epidemiologia. 2021;2(3):360-76.
Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. The Lancet Regional Health–Europe. 2021;11.